This guidance is written in the following context This guidance represents the view of the Institute, which was arrived at after careful consideration of the available evidence. Healthcare professionals are expected to take it fully into account when exercising their clinical judgement. This guidance does not, however, override the individual responsibility of healthcare professionals to make appropriate decisions in the circumstances of the individual patient, in consultation with the patient and/or guardian or carer. Interventional procedures guidance is for healthcare professionals and people using the NHS in England, Wales, Scotland and Northern Ireland. This guidance is endorsed by NHS QIS for implementation by NHSScotland.
Guidance
1.1 Current evidence on the safety and efficacy of therapeutic amnioinfusion for oligohydramnios during pregnancy (excluding labour) does not appear adequate for this procedure to be used without special arrangements for consent and for audit or research. Most of the evidence on the procedure relates to preterm premature rupture of membranes, rather than other causes of oligohydramnios.
1.2
Clinicians wishing to undertake therapeutic amnioinfusion for oligohydramnios during pregnancy (excluding labour) should take the following actions.
• Inform the clinical governance leads in their Trusts.
• Ensure that parents understand the uncertainty about the procedure's safety and efficacy, including the potential risks to the mother, and provide them with clear written information. In addition, use of the Institute's information for patients ('Understanding NICE guidance') is recommended (available from www.nice.org.uk/IPG192publicinfo).
• Audit and review clinical outcomes of all patients having therapeutic amnioinfusion for oligohydramnios during pregnancy (see section 3.1).
1.3
Therapeutic amnioinfusion for oligohydramnios during pregnancy should only be performed in centres specialising in invasive fetal medicine and in the context of a multidisciplinary team, which may include a consultant in fetal medicine, a neonatologist and a specialist midwife.
1.4
Further research will be useful. Clinicians are encouraged to enter patients into well-designed randomised controlled trials comparing therapeutic amnioinfusion with no intervention. The Institute may review the procedure upon publication of further evidence.
2
The procedure 2.1 Indications 2.1.1 An abnormally low volume of amniotic fluid surrounding the fetus is termed oligohydramnios.
2.1.2 Oligohydramnios may be the result of decreased fetal urine production or excretion, or excessive loss of amniotic fluid. Causes of oligohydramnios include premature preterm rupture of amniotic membranes, congenital abnormalities of the fetus's urinary tract, placental insufficiency, twin-to-twin transfusion syndrome, post-maturity (more than 42 weeks' gestation), problems with maternal health, such as high blood pressure, and some medications. Severe oligohydramnios in early pregnancy may lead to the underdevelopment of fetal lung tissue (pulmonary hypoplasia) and limb defects and is associated with poor fetal growth. There is also an increased risk of miscarriage, premature birth and stillbirth.
2.1.3 Oligohydramnios is not routinely treated during pregnancy. There is some evidence that maternal hydration can increase the volume of amniotic fluid.
2.2
Outline of the procedure 2.2.1 Under ultrasound guidance, isotonic fluid, such as normal saline or Ringer's lactate, is infused into the amniotic cavity via a needle inserted through the uterine wall, to restore the volume of amniotic fluid to normal. The procedure may be repeated on a regular basis if oligohydramnios recurs (serial amnioinfusion).
Interventional procedures guidance makes recommendations on the safety and efficacy of a procedure. The guidance does not cover whether or not the NHS should fund a procedure. Decisions about funding are taken by local NHS bodies (primary care trusts and hospital trusts) after considering the clinical effectiveness of the procedure and whether it represents value for money for the NHS.
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Ordering information
Copies of this guidance can be obtained from the NHS Response Line by telephoning 0870 1555 455 and quoting reference number N1134. 'Understanding NICE guidance' can be obtained by quoting reference number N1135.
The distribution list for this guidance is available at www.nice.org.uk/IPG192distributionlist 2.3 Efficacy 2.3.1 A randomised controlled trial of 34 pregnant women reported a significantly lower incidence of pulmonary hypoplasia among fetuses of pregnancies treated with amnioinfusion compared with the controls -(12% (2/17) versus 53%(9/17); relative risk 0.22; 95% confidence interval 0.05 to 0.87, p < 0.05). A non-randomised comparative study reported a rate of pulmonary hypoplasia among neonates of 23% (6/26) in the treated group compared with 31% (4/13) in the control group (not significantly different).
2.3.2 In a randomised controlled trial comparing amnioinfusion with expectant management, neonatal mortality was 6% (1/17) in both the treated group and the control group 6% (1/17). A non-randomised controlled study reported neonatal mortality (excluding stillbirths) of 18% (2/11) in the treated group compared with 71% (5/7) in the expectant-management group (p = 0.05). In another non-randomised comparative study, mortality within the first week after birth was 23% (6/26) in the treated group compared with 38% (5/13) in the expectant-management group (not significantly different). A third non-randomised comparative study reported a survival rate of 73% (8/11) for neonates treated with amnioinfusion and 21% (6/29) for those managed expectantly (p < 0.05). For more details, refer to the 'Sources of evidence' section.
2.3.3
The Specialist Advisers stated that key efficacy outcomes include prolongation of gestation, reduced incidence of pulmonary hypoplasia and improved neonatal survival.
Safety
2.4.1 A non-randomised comparative study including 45 women treated with serial amnioinfusion reported onset of labour shortly after the procedure in one case (2%).
2.4.2 One non-randomised comparative study reported miscarriage in 11% (3/28) of women with unruptured membranes and 21% (5/24) of women with ruptured membranes treated with amnioinfusion. A second non-randomised, retrospective case series reported miscarriage in 12% (2/17) of pregnancies. Four studies reported intrauterine fetal death rates ranging from 0% (0/15) to 14% (4/28) in pregnancies treated with amnioinfusion, and from 0% (0/14) to 38% (11/29) in pregnancies managed expectantly. 
Information for patients
The Institute has produced information describing its guidance on this procedure for parents ('Understanding NICE guidance'). It explains the nature of the procedure and the decision made, and has been written with consent in mind. This information is available from www.nice.org.uk/IPG192publicinfo
Sources of evidence
The evidence considered by the Interventional Procedures Advisory Committee is described in the following document.
'Interventional procedures overview of therapeutic amnioinfusion for oligohydramnios during pregnancy (excluding labour)', April 2006.
Available from: www.nice.org.uk/IP338overview
prgmea.com
